Dr. Karl X. Chai is an associate professor at the Division of Cancer Research, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida. He attended Peking University (PKU, aka Beijing University) and graduated in 1985 with a B.S. in biochemistry. He earned his Ph.D. in biochemistry and molecular biology from the Medical University of South Carolina (MUSC) in 1992 and continued there for post-doctoral research until 1996. Then he began his independent research at the University of Central Florida. He teaches Molecular Biology 1 (PCB3522) and Human Genetics (PCB4663) to undergraduate students in the Burnett School of Biomedical Sciences and whomever else is attracted to these topics. His main research focus is a novel “extracellular membrane-associated serine protease proteolytic activation and action network”, involving the glycosylphosphatidylinositol (GPI)-anchored prostasin (PRSS8), the type-II transmembrane hepsin (TMPRSS1) and matriptase
(PRSS14), and the urokinase-type plasminogen activator (uPA) with its GPI-anchored plasma membrane receptor uPAR.
Dr. Karl X. Chai is an associate professor at the Division of Cancer Research, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida. He attended Peking University (PKU, aka Beijing University) and graduated in 1985 with a B.S. in biochemistry. He earned his Ph.D. in biochemistry and molecular biology from the Medical University of South Carolina (MUSC) in 1992 and continued there for post-doctoral research until 1996. Then he began his independent research at the University of Central Florida. He teaches Molecular Biology 1 (PCB3522) and Human Genetics (PCB4663) to undergraduate students in the Burnett School of Biomedical Sciences and whomever else is attracted to these topics. His main research focus is a novel “extracellular membrane-associated serine protease proteolytic activation and action network”, involving the glycosylphosphatidylinositol (GPI)-anchored prostasin (PRSS8), the type-II transmembrane hepsin (TMPRSS1) and matriptase
(PRSS14), and the urokinase-type plasminogen activator (uPA) with its GPI-anchored plasma membrane receptor uPAR.